Member Info for KonarA

maybe it's about expectations crumbs. Whilst the 1st generation covid vaccines didn't provide sterilising immunity, I had hoped 2nd generation may get closer to it. But 15 of 18 isn't even close. I suspect a big part of the problem was, as Burble says, to do with the time from injection to infection.

@crumbs I've relistened and unfortunately I was correct.

@burble - certainly a valid point on the time from vaccine to infection with omicron. But I wouldn't fancy the sales job of trying to convince someone that a trial of 40 patients where a minimum of 15 of them got covid was a success.

I'm sure the devil may be in the detail of the measured immune response. Not long to wait for the trial readout anyway.

I'll give it another listen. hopefully I am wrong

lots of positivity and reason to buy and hold.

two really troubling negatives though that I think warrant discussion:

1. Of the original 18 patients dosed with covidity, only 3 didn't get Omicron.
2. 40 Patients dosed and now closed. They were approved to recruit up to 80 and have had over 12 months in a global pandemic, and have managed only 40.

I'm excited by Moditope, but covidity sounds a dud to me.

oh and also table 2 - GRP78 in greater quantities than Vimentin and Alpha-Enolase. I wonder if this translates to a more potent response compared to Modi 1?

two things jump out for me here -

1 - another 100% survival rate in mouse models
2 - It talks about volunteer humans demonstrating a TCell response to GPR - does this mean Scancell have dosed them with this to get these results? Or has this come from external data?

@Bermuda

Just digging up this old post to review the schedule of the doses in light of today's post on the M board.

We believe that patient was the first patient in cohort 2 - dosed around the 16th August.

They have stated they are having their 4th dose today, which is 13 weeks from the original dose - but we do know they were on holiday recently. All in all it does seem to be tracking with the dosing schedule that we were given in 2019.

another mab, another possible avidimab benefactor

oh and just one other point... on the trial sites "gearing up". Patient X on cohort 2 stated they were being treated in Liverpool (Clatterbridge Centre and site of the lead investigator). This isn't currently listed as live on the trials registry. So we know there must be more sites live and not just gearing up.

@chester18 - very astute and eloquently put. You pretty much summed up my feelings on this share. I would also add (purely from a personal perspective - and its a drop in the ocean compared to the real significance of clinical results), but just being "right" on this. I've long been telling people of the potential of the moditope platform, and how in my view it is going to be transformational in the fight against cancer. I think a lot of my friends and family have got sick of hearing it from me over the last 8 years. It would be really nice to just go - "see i told you so". Childish I know!

I think with SCIB1 being used in resected melanoma the effects aren't so startling. The evidence of it benefit is in the years of progression free survival, which we saw in the swimlane plot of the phase 1 trial. Moditope is a different beast all together!

One comment that stood out for me was the ability of patient X to swallow easier. The effects of Moditope can be physically felt in the short term and immediately improve quality of life.

I mentioned at the time of the RNS how early very promising results could get clinician enthusiasm and help with recruitment. What I didn't consider was the patient to patient word of mouth enthusiasm. This first patient has potentially recruited another trial patient just from their enthusiasm on a message board. If we continue to see patient's produce results above and beyond the capabilities of checkpoint inhibitors alone, then this trial could fill up and finish very quickly.

thanks Ray. That's a really interesting discovery. So for the time being it does seem that some tailoring of the products to target specific cancers will still be required.

question for those in the know..

given that this new target is based on cirtullination, could it be added as another epitome to Modi 1? What's the rate limiting factor to number of epitopes in the vaccine? Is it ease of manufacturing? Overstimulation of the immune system? Or is it just illogical in that this target is expressed in different cancers?

I know Prof Durrant has previously said there may be synergistic benefits of giving modi 1 and 2 together. What I am just wondering is will Moditope platform ever produce a true "Cancer Vaccine".. one treatment to rule them all!

just the very fact that they were signing deal for Modi 2. My immediate reaction to this mornings news was "so Modi 1 is definitely doing the business then"

avidimab deal could be the fast track to regular royalties. I'm guessing that if we were to outlicence for use in an already licenced product, then it would only be a quick phase 3 trial before commercialisation and royalties (massive assumption on my part there)

@hyms - I was meaning "half an eye towards solving the formulation problems of Moditope as an out-licence" rather than "half an eye towards acquiring Moditope"

Realise that wasn't clear in my original post. No way do I think Vaccitech could acquire Moditope

I've got that pencilled in for 1st week of December ;)

the theory that Lindy is too busy putting together deals to interview certainly carrying more weight today. Odds on another MaB deal in the near future?

This seems like such a tailor made solution to the requirements of formulating a moditope vaccine, that you have to wonder if they had half an eye on moditope when they acquired it.